Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2012, Article ID 969418, 8 pages
http://dx.doi.org/10.1155/2012/969418
Research Article

17 -Ethynyl-androst-5-ene-3 ,7 ,17 -triol (HE3286) Is Neuroprotective and Reduces Motor Impairment and Neuroinflammation in a Murine MPTP Model of Parkinson’s Disease

1Department of Biomedical Sciences, School of Medicine, University of Catania, Via Androne 81, 95124 Catania, Italy
2Department of Immunobiology, Biomedical Primate Research Centre, Lange Kleiweg 161, 2288 GJ Rijswijk, The Netherlands
3Harbor Therapeutics, Inc., 9191 Towne Centre Drive, Suite 409, San Diego, CA 92122, USA
4Tumor Vaccine Group, School of Medicine, University of Washington, Seattle, WA 98109, USA

Received 26 April 2012; Revised 21 August 2012; Accepted 21 August 2012

Academic Editor: Heinz Reichmann

Copyright © 2012 Ferdinando Nicoletti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger, and F. Seitelberger, “Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations,” Journal of the Neurological Sciences, vol. 20, pp. 415–455, 1973. View at Google Scholar
  2. V. Jackson-Lewis and S. Przedborski, “Protocol for the MPTP mouse model of Parkinson's disease,” Nature Protocols, vol. 2, no. 1, pp. 141–151, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Obata, Y. Yamanaka, H. Kinemuchi, and L. Oreland, “Release of dopamine by perfusion with 1-methyl-4-phenylpyridinium ion (MPP+) into the striatum is associated with hydroxyl free radical generation,” Brain Research, vol. 906, no. 1-2, pp. 170–175, 2001. View at Publisher · View at Google Scholar · View at Scopus
  4. G. E. Meredith, S. Totterdell, M. Beales, and C. K. Meshul, “Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease,” Experimental Neurology, vol. 219, no. 1, pp. 334–340, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. I. Kurkowska-Jastrzebska, E. Bałkowiec-Iskra, A. Ciesielska et al., “Decreased inflammation and augmented expression of trophic factors correlate with MOG-induced neuroprotection of the injured nigrostriatal system in the murine MPTP model of Parkinson's disease,” International Immunopharmacology, vol. 9, no. 6, pp. 781–791, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. S. Perkinton, J. K. Ip, G. L. Wood, A. J. Crossthwaite, and R. J. Williams, “Phosphatidylinositol 3-kinase is a central mediator of NMDA receptor signalling to MAP kinase (Erkl/2), Akt/PKB and CREB in striatal neurones,” Journal of Neurochemistry, vol. 80, no. 2, pp. 239–254, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. L. Yang, L. Mao, Q. Tang, S. Samdani, Z. Liu, and J. Q. Wang, “A novel Ca2+-independent signaling pathway to extracellular signal-regulated protein kinase by coactivation of NMDA receptors and metabotropic glutamate receptor 5 in neurons,” Journal of Neuroscience, vol. 24, no. 48, pp. 10846–10857, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Y. Chen and G. Nuñez, “Sterile inflammation: sensing and reacting to damage,” Nature Reviews Immunology, vol. 10, no. 12, pp. 826–837, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. F. Yan, R. Ramasamy, and A. M. Schmidt, “The RAGE axis a fundamental mechanism signaling danger to the vulnerable vasculature,” Circulation Research, vol. 106, no. 5, pp. 842–853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Pisetsky, “Cell death in the pathogenesis of immune-mediated diseases: the role of HMGB1 and DAMP-PAMP complexes,” Swiss Medical Weekly, vol. 141, article w13256, 2011. View at Google Scholar
  11. H. M. Gao, H. Zhou, F. Zhang, B. C. Wilson, W. Kam, and J. S. Hong, “HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration,” Journal of Neuroscience, vol. 31, no. 3, pp. 1081–1092, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. X. Hu, D. Zhang, H. Pang et al., “Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease,” Journal of Immunology, vol. 181, pp. 7194–7204, 2008. View at Google Scholar
  13. C. N. Ahlem, M. R. Kennedy, T. M. Page et al., “Studies of the pharmacology of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol, a synthetic anti-inflammatory androstene,” International Journal of Clinical and Experimental Medicine, vol. 4, no. 2, pp. 119–135, 2011. View at Google Scholar · View at Scopus
  14. D. L. Auci, C. N. Ahlem, M. R. Kennedy, T. M. Page, C. L. Reading, and J. M. Frincke, “A potential role for 5-androstene-3β,7β,17β-triol in obesity and metabolic syndrome,” Obesity, vol. 19, no. 4, pp. 806–811, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. C. N. Ahlem, D. L. Auci, F. Nicoletti et al., “Pharmacology and immune modulating properties of 5-androstene-3β,7β,17β-triol, a DHEA metabolite in the human metabolome,” Journal of Steroid Biochemistry and Molecular Biology, vol. 126, no. 3–5, pp. 87–94, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. D. L. Auci, L. Kaler, S. Subramanian et al., “A new orally bioavailable synthetic androstene inhibits collagen-induced arthritis in the mouse: androstene hormones as regulators of regulatory T cells,” Annals of the New York Academy of Sciences, vol. 1110, pp. 630–640, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. M. Kosiewicz, D. L. Auci, P. Fagone et al., “HE3286, an orally bioavailable synthetic analogue of an active DHEA metabolite suppresses spontaneous autoimmune diabetes in the non-obese diabetic (NOD) mouse,” European Journal of Pharmacology, vol. 658, no. 2-3, pp. 257–262, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Ahlem, D. Auci, K. Mangano et al., “HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease,” Annals of the New York Academy of Sciences, vol. 1173, pp. 781–790, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. C. L. Reading, J. M. Frincke, and S. K. White, “Molecular targets for 17α-ethynyl-5-androstene-3β,7β,17β-triol, an anti-inflammatory agent derived from the human metabolome,” PLoS One, vol. 7, article e32147, 2012. View at Google Scholar
  20. M. Lu, D. Patsouris, P. Li et al., “A new antidiabetic compound attenuates inflammation and insulin resistance in Zucker diabetic fatty rats,” American Journal of Physiology, vol. 298, no. 5, pp. E1036–E1048, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Subramaniam and K. Unsicker, “ERK and cell death: ERK1/2 in neuronal death,” FEBS Journal, vol. 277, no. 1, pp. 22–29, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. B. J. Turunen, H. Ge, J. Oyetunji et al., “Paclitaxel succinate analogs: anionic and amide introduction as a strategy to impart blood-brain barrier permeability,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 22, pp. 5971–5974, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. X. Liu, M. Tu, R. S. Kelly, C. Chen, and B. J. Smith, “Development of a computational approach to predict blood-brain barrier permeability,” Drug Metabolism and Disposition, vol. 32, no. 1, pp. 132–139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. D. D. Dischino, M. J. Welch, M. R. Kilbourn, and M. E. Raichle, “Relationship between lipophilicity and brain extraction of C-11-labeled radiopharmaceuticals,” Journal of Nuclear Medicine, vol. 24, no. 11, pp. 1030–1038, 1983. View at Google Scholar · View at Scopus
  25. S. Fasano, E. Bezard, A. D'Antoni et al., “Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, pp. 21824–21829, 2010. View at Google Scholar
  26. V. Jackson-Lewis, M. Jakowec, R. E. Burke, and S. Przedborski, “Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine,” Neurodegeneration, vol. 4, no. 3, pp. 257–269, 1995. View at Google Scholar · View at Scopus
  27. W. G. Tatton, C. E. Greenwood, N. A. Seniuk, and P. T. Salo, “Interactions between MPTP-induced and age-related neuronal death in a murine model of Parkinson's disease,” Canadian Journal of Neurological Sciences, vol. 19, no. 1, pp. 124–133, 1992. View at Google Scholar · View at Scopus
  28. E. Brouillet and M. F. Beal, “NMDA antagonists partially protect against MPTP induced neurotoxicity in mice,” NeuroReport, vol. 4, no. 4, pp. 387–390, 1993. View at Google Scholar · View at Scopus
  29. J. B. Schulz, R. T. Matthews, M. M. K. Muqit, S. E. Browne, and M. F. Beal, “Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice,” Journal of Neurochemistry, vol. 64, no. 2, pp. 936–939, 1995. View at Google Scholar · View at Scopus
  30. M. Maroso, S. Balosso, T. Ravizza et al., “Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures,” Nature Medicine, vol. 16, no. 4, pp. 413–419, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Agulhon, M. Y. Sun, T. Murphy, T. Myers, K. Lauderdale, and T. A. Fiacco, “Calcium signaling and gliotransmission in normal versus reactive astrocytes,” Frontiers in Pharmacology, vol. 3, article 139, 2012. View at Google Scholar
  32. D. Conrad, A. Wang, R. Pieters et al., “HE3286, an oral synthetic steroid, treats lung inflammation in mice without immune suppression,” Journal of Inflammation, vol. 7, article 52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. P. C. Orban, P. F. Chapman, and R. Brambilla, “Is the Ras-MAPK signalling pathway necessary for long-term memory formation?” Trends in Neurosciences, vol. 22, no. 1, pp. 38–44, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Cagnol and J. C. Chambard, “ERK and cell death: mechanisms of ERK-induced cell death—apoptosis, autophagy and senescence,” FEBS Journal, vol. 277, no. 1, pp. 2–21, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. L. Xiao, C. Hu, C. Feng, and Y. Chen, “Switching of N-Methyl-D-aspartate (NMDA) receptor-favorite intracellular signal pathways from ERK1/2 protein to p38 mitogen-activated protein kinase leads to developmental changes in NMDA neurotoxicity,” Journal of Biological Chemistry, vol. 286, no. 23, pp. 20175–20193, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. W. Kim, C. M. Lim, J. B. Kim et al., “Extracellular HMGB1 released by NMDA treatment confers neuronal apoptosis via RAGE-p38 MAPK/ERK signaling pathway,” Neurotoxicity Research, vol. 20, pp. 159–169, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. A. Vezzani, M. Maroso, S. Balosso, M. A. Sanchez, and T. Bartfai, “IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures,” Brain, Behavior, and Immunity, vol. 25, pp. 1281–1289, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. E. D. Crown, Y. S. Gwak, Z. Ye, K. M. Johnson, and C. E. Hulsebosch, “Activation of p38 MAP kinase is involved in central neuropathic pain following spinal cord injury,” Experimental Neurology, vol. 213, no. 2, pp. 257–267, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. Z. Liu, C. Lv, W. Zhao, Y. Song, D. Pei, and T. Xu, “NR2B-containing NMDA receptors expression and their relationship to apoptosis in hippocampus of Alzheimer's disease-like rats,” Neurochemical Research, vol. 37, no. 7, pp. 1420–1427, 2012. View at Google Scholar